Reaction
Papillary Thyroid Cancer reporting signals
As of the last recalculation, Papillary Thyroid Cancer appears in 1,704 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is BLEOMYCIN SULFATE (PRR 27.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bleomycin Sulfate | 23 | 27.6 | 27.6 |
| Exenatide | 105 | 25.9 | 26.0 |
| Liraglutide | 90 | 23.4 | 23.5 |
| Liothyronine Sodium | 13 | 18.4 | 18.4 |
| Alemtuzumab | 24 | 15.4 | 15.4 |
| Minocycline | 14 | 14.8 | 14.8 |
| Sorafenib | 19 | 11.3 | 11.3 |
| Dabrafenib | 18 | 10.5 | 10.5 |
| Lithium | 21 | 10.3 | 10.3 |
| Lithium Bromatum | 21 | 10.3 | 10.3 |
| Thiotepa | 8 | 10.3 | 10.3 |
| Methimazole | 6 | 9.4 | 9.4 |
| Everolimus Tablets | 12 | 8.8 | 8.8 |
| Oral Semaglutide | 51 | 8.7 | 8.7 |
| Ifosfamide | 12 | 6.9 | 6.9 |
| Dolutegravir Sodium | 5 | 6.8 | 6.8 |
| Trametinib | 13 | 6.6 | 6.6 |
| Cladribine | 5 | 6.4 | 6.4 |
| Pioglitazone | 22 | 6.3 | 6.3 |
| Cisplatin | 37 | 5.9 | 5.9 |
| Etoposide | 34 | 5.7 | 5.7 |
| Tirzepatide | 59 | 4.6 | 4.6 |
| Vemurafenib | 4 | 4.1 | 4.1 |
| Dimethyl Fumarate | 39 | 3.9 | 3.9 |
| Natalizumab | 54 | 3.7 | 3.7 |
| Dulaglutide | 20 | 2.8 | 2.8 |
| Somatropin | 16 | 2.7 | 2.7 |
| Ixekizumab | 7 | 2.3 | 2.3 |
| Cinacalcet Hydrochloride | 7 | 1.8 | 1.8 |
| Galcanezumab-Gnlm | 4 | 1.6 | 1.6 |